James Matthew Meinig

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignee: Oregon Health & Science University. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Matthew Meinig. Retrieved from https://idiyas.com/inventor/james-matthew-meinig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 44(Granted Patents)

Company Filing History:

6 out of 524

Oregon Health & Science University

patents

Years Active: 2017-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11325886 - Amide compounds, pharmaceutical compositions thereof, and methods of using the same (2022-05-10),

2. 11104654 - Derivatives of sobetirome (2021-08-31),

3. 10870616 - Derivatives of sobetirome (2020-12-22),

4. 10544075 - Derivatives of sobetirome (2020-01-28),

5. 10392356 - Derivatives of sobetirome (2019-08-27),

6. 9701650 - Derivatives of sobetirome (2017-07-11),

Title: James Matthew Meinig: Innovator in Pharmaceutical Compounds

Introduction

James Matthew Meinig is a prominent inventor based in Portland, OR (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating neurodegenerative diseases. With a total of 6 patents to his name, Meinig's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents, Meinig has developed amide compounds and pharmaceutical compositions that utilize these compounds. These amide compounds are disclosed alongside methods for treating neurodegenerative diseases, which involve administering the compounds or pharmaceutical compositions to a subject. Additionally, he has worked on ester derivatives of sobetirome, which are designed to enhance central nervous system (CNS) distribution.

Career Highlights

James Matthew Meinig is affiliated with Oregon Health & Science University, where he continues to advance his research and innovation in pharmaceutical sciences. His work is characterized by a commitment to improving treatment options for patients suffering from complex neurological conditions.

Collaborations

Meinig has collaborated with notable colleagues, including Thomas S. Scanlan and Tapasree Banerji, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

James Matthew Meinig's contributions to pharmaceutical inventions highlight his dedication to addressing critical health challenges. His innovative work continues to pave the way for advancements in the treatment of neurodegenerative diseases.

Profile summary based on public USPTO records.